Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

EHA 2021

9 - 17 Jun 2021

Virtual, Netherlands

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM

Prof Thierry Facon - Chu De Lille, Lille, France

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore

The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng - National University of Singapore, Singapore )

Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients

Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA

$Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-refractory multiple myeloma patients ( Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA )$

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

Dr Claudio Cerchione - IRCCS, Meldola, Italy

$Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )$

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

Prof John Allan - Weill Cornell Medicine, New York, USA

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia chromosome-positive ALL

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia chromosome-positive ALL ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo

EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL

Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands

GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma

Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma ( Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark )

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma

Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

More from ecancer